Dr. Wei-Feng CHEN (2003)
Immunologist. Born in Shanghai. Graduated from School
of Medicine, Beijing Medical College in 1958; conferred
with PhD of Medical Biology, Melbourne University, Australia
in 1982; Professor of immunology, Peking University
Health Science Center. Academician, Chinese Academy
of Sciences. President, Chinese Society of Immunology.
Editorial Board Member of many prestigious Chinese biological
and medical journals.
Dr. Chen systematically studied intrathymic T cell
development. He has demonstrated that T cell receptor
(TCR) gene rearrangement is initiated at early T cell
(CD3-CD4-CD8-) stage in mouse thymus; unveiled thymocyte
functional competence is acquired in thymic medulla
and the functional maturation is a programmed process
with stepwise acquisition of functional capacity and
specialty. He disclosed the continuation of thymic selection
processed in thymic medulla for medullary-type thymocyte
functional maturation and further depletion by apoptosis.
Since late 1997, he has engaged in the study of T cell
vaccination for cancer immunotherapy and looking for
the genes for early detection of cancer. It is also
in the attempt to identify genes relevant to cancer
cell behavior. His group has identified several novel
cancer-testis antigens and cloned their encoding genes
from human hepatocellular carcinoma (HCC). They have
revealed that a substantial number of HCC patients possess
T cell response specific to the HLA-A2-presented peptides
of NY-ESO-1 and MAGE-3 by IFNƒÁ-release ELISPOT and/or
intracellular-IFNƒÁ assays. It is the basis for the preparation
of tumor antigen vaccine. Meanwhile, the detection of
CT gene transcripts in PBMC is a means to reveal the
early metastasis and prognosis of HCC patients.